GALT.US Galectin Therapeutics Inc

Healthcare Biotechnology USA Stocks
3.05 USD
Close of Nov 13, 2026
2.03 7.13
Market cap
USD 308M
P/E
-
P/B
207.70x
ROE
-
Dividend yield
0.04%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GALT.US undervalued?

Graham number

The Graham number of Galectin Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Galectin Therapeutics Inc fundamental analysis

No fundamental analysis for Galectin Therapeutics Inc yet.

Galectin Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc…

Full company profile